Should I buy or sell Karyopharm Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks .

What is Karyopharm Therapeutics' stock price target for 2024?

5 brokers have issued 12-month price targets for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 351.5% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts .

How have KPTI shares performed in 2024?

Karyopharm Therapeutics' stock was trading at $0.8650 at the start of the year. Since then, KPTI shares have increased by 45.1% and is now trading at $1.2550. View the best growth stocks for 2024 here .

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KPTI earnings forecast .

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.07. The business had revenue of $33.75 million for the quarter, compared to analysts' expectations of $33.50 million. During the same period in the previous year, the company earned ($0.43) earnings per share.

What ETF holds Karyopharm Therapeutics' stock?

iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.0 million-$160.0 million, compared to the consensus revenue estimate of $152.0 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com . Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , CRISPR Therapeutics (CRSP) , Alibaba Group (BABA) , Micron Technology (MU) , Invitae (NVTA) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY) .

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KPTI Stock Alerts

$1.22

-0.06 (-4.69%)

(As of 02:09 PM ET)

Compare

Today's Range: $1.22
▼
$1.31
50-Day Range: $1.10
▼
$1.58
52-Week Range: $0.62
▼
$4.11

Volume: 725,773 shs
Average Volume: 1.66 million shs
Market Capitalization: $140.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Get Karyopharm Therapeutics alerts:

Karyopharm Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 351.5% Upside
$5.67 Price Target
Short Interest: Bearish
19.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$198,175 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.19) to ($1.05) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

304th out of 918 stocks

Pharmaceutical Preparations Industry

128th out of 424 stocks

3.3

Analyst's Opinion

Consensus Rating
Karyopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Karyopharm Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.94% of the outstanding shares of Karyopharm Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Karyopharm Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Karyopharm Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Karyopharm Therapeutics does not currently pay a dividend.
Dividend Growth
Karyopharm Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Karyopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Karyopharm Therapeutics is -1.11.

0.0

News and Social Media Coverage

Search Interest
Only 4 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,175.00 in company stock.
Percentage Held by Insiders
Only 3.32% of the stock of Karyopharm Therapeutics is held by insiders.
Percentage Held by Institutions
66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.19) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Karyopharm Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Karyopharm Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KPTI Stock News Headlines

April 1, 2024 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 15, 2024 | finance.yahoo.com

KPTI Apr 2024 5.000 call

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 15, 2024 | finance.yahoo.com

KPTI Apr 2024 1.500 put

March 14, 2024 | businesswire.com

Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO ® (selinexor)

March 6, 2024 | finance.yahoo.com

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

March 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)

March 5, 2024 | finance.yahoo.com

Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 2, 2024 | seekingalpha.com

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

March 1, 2024 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | finance.yahoo.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

February 29, 2024 | fool.com

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

February 29, 2024 | finance.yahoo.com

Q4 2023 Karyopharm Therapeutics Inc Earnings Call

February 29, 2024 | finanznachrichten.de

Karyopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

February 29, 2024 | msn.com

Karyopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08M

February 29, 2024 | markets.businessinsider.com

Karyopharm Therapeutics Inc. Q4 Loss misses estimates

February 29, 2024 | finance.yahoo.com

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

February 28, 2024 | benzinga.com

Karyopharm Therapeutics's Earnings: A Preview

February 27, 2024 | finance.yahoo.com

KPTI Mar 2024 1.000 put

February 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)

February 25, 2024 | ca.finance.yahoo.com

KPTI Mar 2024 1.500 call

February 25, 2024 | investorplace.com

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

February 23, 2024 | benzinga.com

Karyopharm Therapeutics Stock (NASDAQ:KPTI) Earnings Dates and Earning Calls

February 23, 2024 | benzinga.com

Karyopharm Therapeutics Stock (NASDAQ:KPTI) Insider Trades

February 22, 2024 | benzinga.com

Karyopharm Therapeutics Stock (NASDAQ:KPTI), Short Interest Report

February 22, 2024 | finance.yahoo.com

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

See More Headlines

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KPTI
CUSIP: N/A
CIK: 1503802
Web: www.karyopharm.com
Phone: (617) 658-0600
Fax: N/A
Employees: 325
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.67
High Stock Price Target: $10.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +342.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-143,100,000.00
Net Margins: -97.99%
Pretax Margin: -97.77%
Return on Equity: N/A
Return on Assets: -50.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.37
Quick Ratio: 3.32

Sales & Book Value

Annual Sales: $146.03 million
Price / Sales: 1.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.19) per share
Price / Book: -1.08

Miscellaneous

Outstanding Shares: 115,070,000
Free Float: 111,247,000
Market Cap: $147.29 million
Optionable: Optionable
Beta: 0.03

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Richard A. Paulson M.B.A. (Age 57)
President, CEO & Director
Comp: $1.36M
Dr. Sharon Shacham M.B.A. (Age 54)
Ph.D., Co-Founder & Chairman of Scientific Advisory Board
Comp: $1.4M
Mr. Michael P. Mason CPA (Age 49)
M.B.A., Executive VP, CFO & Treasurer
Comp: $681.59k
Mr. Michael J. Mano J.D. (Age 47)
Senior VP, General Counsel & Secretary
Comp: $625.08k
Ms. Sohanya Cheng M.B.A. (Age 41)
Executive VP & Chief Commercial Officer
Comp: $664.3k
Mr. Stuart Poulton
Executive VP & Chief Development Officer
Dr. Mansoor Raza Mirza M.D. (Age 63)
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Comp: $150k
Mr. Cameron Peters (Age 64)
Vice President of Finance, Assistant Treasurer & Principal Accounting Officer
Ms. Elhan Webb C.F.A.
Senior Vice President of Investor Relations
Mr. James Accumanno J.D.
Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KPTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.
What is Karyopharm Therapeutics' stock price target for 2024?: 5 brokers have issued 12-month price targets for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 351.5% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.
How have KPTI shares performed in 2024?: Karyopharm Therapeutics' stock was trading at $0.8650 at the start of the year. Since then, KPTI shares have increased by 45.1% and is now trading at $1.2550.
View the best growth stocks for 2024 here.
When is Karyopharm Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KPTI earnings forecast.
How were Karyopharm Therapeutics' earnings last quarter?: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.07. The business had revenue of $33.75 million for the quarter, compared to analysts' expectations of $33.50 million. During the same period in the previous year, the company earned ($0.43) earnings per share.
What ETF holds Karyopharm Therapeutics' stock?: iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?: Karyopharm Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.0 million-$160.0 million, compared to the consensus revenue estimate of $152.0 million.
What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?: 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.
What other stocks do shareholders of Karyopharm Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).
How do I buy shares of Karyopharm Therapeutics?: Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KPTI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial